105 related articles for article (PubMed ID: 23645760)
21. Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment.
Yamasaki F; Kurisu K; Aoki T; Yamanaka M; Kajiwara Y; Watanabe Y; Takayasu T; Akiyama Y; Sugiyama K
Eur J Radiol; 2012 Oct; 81(10):2805-10. PubMed ID: 22100373
[TBL] [Abstract][Full Text] [Related]
22. Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma.
Shapiro LQ; Beal K; Goenka A; Karimi S; Iwamoto FM; Yamada Y; Zhang Z; Lassman AB; Abrey LE; Gutin PH
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):636-42. PubMed ID: 22765876
[TBL] [Abstract][Full Text] [Related]
23. Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children.
Goldenberg NA; Knapp-Clevenger R; Manco-Johnson MJ;
N Engl J Med; 2004 Sep; 351(11):1081-8. PubMed ID: 15356305
[TBL] [Abstract][Full Text] [Related]
24. A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma.
Pace A; Mandoj C; Antenucci A; Villani V; Sperduti I; Casini B; Carosi M; Fabi A; Vidiri A; Koudriavtseva T; Conti L
J Neurooncol; 2018 Jul; 138(3):527-535. PubMed ID: 29594657
[TBL] [Abstract][Full Text] [Related]
25. The VIDAS D-dimer test for venous thromboembolism: a prospective surveillance study shows maintenance of sensitivity and specificity when used in normal clinical practice.
Mountain D; Jacobs I; Haig A
Am J Emerg Med; 2007 May; 25(4):464-71. PubMed ID: 17499668
[TBL] [Abstract][Full Text] [Related]
26. 10 Questions about the use of bevacizumab in the management of recurrent malignant gliomas.
Chamberlain MC
Neurologist; 2010 Jan; 16(1):56-60. PubMed ID: 20065801
[No Abstract] [Full Text] [Related]
27. Prognostic significance of elevated D-dimer for survival in patients with sarcoma.
Raj SD; Zhou X; Bueso-Ramos CE; Ravi V; Patel S; Benjamin RS; Vadhan-Raj S
Am J Clin Oncol; 2012 Oct; 35(5):462-7. PubMed ID: 21654313
[TBL] [Abstract][Full Text] [Related]
28. Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T.
Grabner G; Nöbauer I; Elandt K; Kronnerwetter C; Woehrer A; Marosi C; Prayer D; Trattnig S; Preusser M
Magn Reson Imaging; 2012 Jan; 30(1):139-47. PubMed ID: 21982163
[TBL] [Abstract][Full Text] [Related]
29. The negative predictive value of D-dimer on the risk of recurrent venous thromboembolism in patients with multiple previous events: a prospective cohort study (the PROLONG PLUS study).
Ageno W; Cosmi B; Ghirarduzzi A; Santoro R; Bucherini E; Poli D; Prisco D; Alatri A; Pengo V; Galli L; Dentali F; Palareti G
Am J Hematol; 2012 Jul; 87(7):713-5. PubMed ID: 22488507
[TBL] [Abstract][Full Text] [Related]
30. Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study.
Cosmi B; Legnani C; Tosetto A; Pengo V; Ghirarduzzi A; Testa S; Prisco D; Poli D; Tripodi A; Palareti G; ;
Thromb Haemost; 2010 Jun; 103(6):1152-60. PubMed ID: 20352167
[TBL] [Abstract][Full Text] [Related]
31. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Mrugala MM
Neurology; 2009 Feb; 72(8):773; author reply 773-4. PubMed ID: 19248218
[No Abstract] [Full Text] [Related]
32. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients.
Norden AD; Bartolomeo J; Tanaka S; Drappatz J; Ciampa AS; Doherty LM; Lafrankie DC; Ruland S; Quant EC; Beroukhim R; Wen PY
J Neurooncol; 2012 Jan; 106(1):121-5. PubMed ID: 21706358
[TBL] [Abstract][Full Text] [Related]
33. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy.
Sallah S; Husain A; Sigounas V; Wan J; Turturro F; Sigounas G; Nguyen NP
Clin Cancer Res; 2004 Nov; 10(21):7238-43. PubMed ID: 15534097
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of bevacizumab therapy in recurrent malignant gliomas in relation to the prior recurrence pattern or tumor location.
Matsuda M; Ishikawa E; Yamamoto T; Akutsu H; Takano S; Matsumura A
J Clin Neurosci; 2017 Jun; 40():115-119. PubMed ID: 28246006
[TBL] [Abstract][Full Text] [Related]
35. Potential use of D-dimer measurement in patients treated with oral anticoagulant for a venous thromboembolic episode.
Ombandza-Moussa E; Samama MM; Horellou MH; Elalamy I; Conard J
Int Angiol; 2003 Dec; 22(4):364-9. PubMed ID: 15153820
[TBL] [Abstract][Full Text] [Related]
36. Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer.
Akun E; Okutur K; Seber S; Korkmaz T; Aydin K; Bozkurt M; Namal E; Hasbal B; Tecimer C; Demir G
J BUON; 2012; 17(4):669-76. PubMed ID: 23335523
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of Wells score and repeated D-dimer in diagnosing venous thromboembolism.
Ljungqvist M; Söderberg M; Moritz P; Ahlgren A; Lärfars G
Eur J Intern Med; 2008 Jun; 19(4):285-8. PubMed ID: 18471679
[TBL] [Abstract][Full Text] [Related]
38. Safety of bevacizumab in patients with malignant gliomas: a systematic review.
Simonetti G; Trevisan E; Silvani A; Gaviani P; Botturi A; Lamperti E; Beecher D; Bertero L; Bosa C; Salmaggi A
Neurol Sci; 2014 Jan; 35(1):83-9. PubMed ID: 24281944
[TBL] [Abstract][Full Text] [Related]
39. A Retrospective Evaluation of Bevacizumab Treatment in Patients with Progressive Malignant Glioma in Northern Sweden.
Sandström M; Laudius M; Lindqvist T; Asklund T; Johansson M
Anticancer Res; 2017 Apr; 37(4):1869-1874. PubMed ID: 28373454
[TBL] [Abstract][Full Text] [Related]
40. Bevacizumab Use and the Risk of Arterial and Venous Thromboembolism in Patients with High-Grade Gliomas: A Nested Case-Control Study.
Lee I; Adimadhyam S; Nutescu EA; Zhou J; Asfaw AA; Sweiss KI; Patel PR; Calip GS
Pharmacotherapy; 2019 Sep; 39(9):921-928. PubMed ID: 31332810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
